Thus, in vivo and in vitro evidence in breast cancer cells support adjuvant melatonin-sensitized therapy-resistant, primary HER2-positive breast cancer cells for chemotherapy through increased oxidative stress in the endoplasmic reticulum [40]. The gene discussed is ERBB2; the disease is breast carcinoma.